Philadelphia, Pennsylvania--(Newsfile Corp. - March 20, 2024) - A recently filed securities complaint alleges that, at relevant times and in Secondary Public Offering materials, agilon health, inc., (NYSE: AGL) via certain of its officers and directors, misled investors about agilon's medical costs by: (1) touting the Company's purported visibility into utilization trends and medical costs; (2) failing to disclose increased medical costs that agilon had incurred due to higher utilization of healthcare by MA patients; (3) falsely stating that its accounting reserves for higher-than-expected medical costs were adequate; (4) making false and misleading statements about the effectiveness of its business model; (5) issuing overly optimistic financial guidance; and (6) issuing risk disclosures that were materially false and misleading because they characterized adverse facts that had already materialized as mere possibilities.

Current agilon shareholders who have held agilon stock since prior to January 9, 2023, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever.

If you would like to learn more about this matter, you are encouraged to visit , email Joshua Grabar at jgrabar@grabarlaw.com or Mia Heller at mheller@grabarlaw.com, or call us at 267-507-6085.
$AGL #agilon

Attorney Advertising Disclaimer

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com